Asparaginase decreases clotting factors in vitro: a possible pitfall?

Int J Clin Lab Res. 1995;25(3):146-8. doi: 10.1007/BF02592556.

Abstract

L-Asparaginase treatment of leukemia patients causes hemostatic problems. To investigate whether L-asparaginase influences coagulation studies, 63 blood samples of 21 healthy male donors were incubated with L-asparaginase for 30 min at room temperature. After treatment with 100 IU/ml L-asparaginase plasma fibrinogen (P = 0.002), plasma antithrombin (P = 0.0002), plasma protein C (P = 0.0004), and plasma plasminogen (P = 0.0039) were decreased compared with controls. In contrast, a significant increase in plasma von Willebrand factor antigen (P = 0.08) and plasma thromboglobulin (P = 0.005) was observed. The decrease in plasma anti-thrombin (P = 0.001), plasma protein C (P = 0.0003), and plasma plasminogen (P = 0.0043) was also measurable after 0.05 IU/ml asparaginase treatment. The incubation with L-asparaginase was similar to the normal time from blood sampling to testing and hence the results suggest that L-asparaginase may directly attack proteins of the coagulation system during the interval between sampling and assay.

MeSH terms

  • Adult
  • Antithrombin III / metabolism
  • Asparaginase / metabolism*
  • Blood Coagulation Factors / metabolism*
  • Fibrinogen / metabolism
  • Humans
  • In Vitro Techniques
  • Male
  • Protein C / metabolism
  • Protein S / metabolism
  • Time Factors
  • von Willebrand Factor / metabolism

Substances

  • Blood Coagulation Factors
  • Protein C
  • Protein S
  • von Willebrand Factor
  • Antithrombin III
  • Fibrinogen
  • Asparaginase